^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
LAE005
i
Other names: LAE005, FAZ053, FAZ-053, FAZ 053, LAE-005, LAE 005
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Laekna Therap, Novartis
Drug class:
PD-L1 inhibitor
Related drugs:
11ms
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (clinicaltrials.gov)
P1, N=154, Terminated, Novartis Pharmaceuticals | Active, not recruiting --> Terminated; The early termination was based on a business decision that FAZ053 would no longer be formulated and was not a consequence of any safety concern.
Trial termination
|
spartalizumab (PDR001) • LAE005
almost2years
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (clinicaltrials.gov)
P1, N=154, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Jun 2024 --> Nov 2024 | Trial primary completion date: Jun 2024 --> Nov 2024
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
spartalizumab (PDR001) • LAE005
almost2years
PhI to Solid Tumors and PhII to Locally Advanced or mTNBC (clinicaltrials.gov)
P1, N=21, Completed, Laekna Limited | Recruiting --> Completed
Trial completion
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • PTEN (Phosphatase and tensin homolog) • BRCA (Breast cancer early onset) • PI3K (Phosphoinositide 3-kinases)
|
PD-L1 expression • PGR expression
|
albumin-bound paclitaxel • afuresertib (LAE002) • LAE005
Share via
